AN ACT to amend Tennessee Code Annotated, Title 53 and Title 63, relative to buprenorphine.
Impact
This legislation reflects a significant effort to enhance patient safety and awareness concerning the use of buprenorphine, which is commonly used in the treatment of opioid dependence. The requirement for a signed acknowledgment serves to create a formal record that patients have been educated about the risks, such as neonatal abstinence syndrome, which can occur in infants born to mothers using this medication. Public health authorities will also be responsible for developing and disseminating educational materials on these topics, which will further bolster patient knowledge and safety.
Summary
Senate Bill 733 (SB0733) is an act aimed at amending the Tennessee Code Annotated, specifically Title 53 and Title 63, to introduce regulations regarding the prescription of buprenorphine products. The bill mandates that healthcare providers must obtain a signed acknowledgment from patients before issuing an initial prescription of buprenorphine. This is intended to ensure that patients are fully informed about the medication and its associated risks, particularly in terms of use during pregnancy and the potential effects on unborn infants.
Contention
Notable points of contention regarding SB0733 could arise from the implications for healthcare providers, particularly concerning the administrative burden of obtaining and maintaining the acknowledgment forms. While the bill aims to protect patients, there may be concerns regarding access to necessary treatments for those in need of buprenorphine, particularly if healthcare providers feel constrained by the added regulatory requirements. Discussions in legislative committees preceding the bill's introduction may have highlighted these concerns, balancing patient safety with the need for timely and effective addiction treatment options.